118 related articles for article (PubMed ID: 27244099)
1. Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
Yang S; Leone D; Frydenlund N; Hoang M; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Melanoma Res; 2016 Aug; 26(4):361-6. PubMed ID: 27244099
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
4. Differing biologic behaviors of desmoplastic melanoma subtypes: Insights based on histopathologic, immunohistochemical, and genetic analyses.
Yang K; Mahalingam M
J Am Acad Dermatol; 2020 Aug; 83(2):523-531. PubMed ID: 32068045
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
8. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
11. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
12. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?
Mitchell B; Leone DA; Feller JK; Yang S; Mahalingam M
Hum Pathol; 2016 Jun; 52():19-27. PubMed ID: 26980024
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
Lade-Keller J; Yuusufi S; Riber-Hansen R; Steiniche T; Stougaard M
Melanoma Res; 2018 Oct; 28(5):398-409. PubMed ID: 29570169
[TBL] [Abstract][Full Text] [Related]
15. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites.
Cheng KA; Kurtis B; Babayeva S; Zhuge J; Tantchou I; Cai D; Lafaro RJ; Fallon JT; Zhong M
Ann Diagn Pathol; 2015 Jun; 19(3):146-8. PubMed ID: 25862495
[TBL] [Abstract][Full Text] [Related]
18. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.
Roh MR; Park KH; Chung KY; Shin SJ; Rha SY; Tsao H
Am J Cancer Res; 2017; 7(1):134-138. PubMed ID: 28123854
[TBL] [Abstract][Full Text] [Related]
19. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
20. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
